ParkourSC acquired Quartic to create a unified AI platform that connects manufacturing, clinical, distribution, and healthcare data across the entire life sciences supply chain, enabling faster disposition decisions and higher batch yields in regulated environments.
- End-to-end visibility: The platform connects manufacturing data with clinical, distribution, and healthcare data to predict and prevent supply chain risks across the entire product lifecycle.
- Dramatic efficiency gains: Fit-for-use disposition decisions have been reduced from three days to one minute, with 15-20% higher batch yields in biologics manufacturing.
- Integrated management: Deviation, verification, release, excursion, disposition, and regulatory documentation are all managed in one place with pre-defined guardrails.
- No system replacement needed: The platform sits above existing MES, LIMS, QMS, historian, and logistics systems, requiring no infrastructure changes.
- Knowledge transfer: Process understanding and quality attributes built during clinical manufacturing now inform commercial manufacturing and distribution decisions.
ParkourSC acquired Quartic, bringing together ParkourSC’s clinical and commercial supply chain AI with Quartic’s manufacturing AI to create a single, unified platform purpose-built for regulated life sciences and healthcare.
By connecting manufacturing data with clinical, distribution, and healthcare data, the unified AI platform can predict which batches, lots, and shipments are at risk and prescribe the best course of action, whether that is adjusting a process, rerouting a shipment, prioritizing inventory, or accelerating release.
“In the past, life sciences companies never had a connected view of a product from its first batch to commercial distribution,” says Mahesh Veerina, president and CEO of ParkourSC. “This changes today through our acquisition of Quartic, where we can finally close that gap with an end-to-end intelligence platform with proven GxP foundation that will serve as the definitive standard for autonomous regulated supply chains.”
“The most important facts about a batch are established when it is made, but they are needed long after it leaves the plant,” says Rajiv Anand, CEO and co-founder of Quartic. “Connecting manufacturing and supply chain data puts the full history of the product in front of the people making release, disposition, and scale-up decisions and ensures the quality of the product that ultimately gets delivered to patients.”
Both companies are purpose-built for regulated life sciences and already share customers. Documented outcomes include fit-for-use disposition decisions cut from three days to one minute, and 15-20% higher batch yield in biologics manufacturing. The platform sits above the MES, LIMS, QMS, historian, and logistics systems customers already run, so neither customers nor their partners need to replace them.”
Key takeaways:
· Deviation, verification, release, excursion, disposition, and regulatory documentation are all managed in one place, within pre-defined guardrails.
· The platform knows how each batch was made and how much stability margin it carried out of the plant. When an excursion or quality question arises, disposition starts from that evidence, not a new investigation. Batches released near the edge of specification can be protected before a disruption occurs.
· Knowledge of the attributes that affect patient safety and efficacy, and the root causes behind their variation, moves forward from clinical manufacturing into commercial manufacturing and distribution. It is no longer rebuilt at each handoff.
· Process understanding built in clinical batches informs scale-up and technology transfer, shortening the path to commercial supply.
